Publication at Central Library of Charles University |
2012
Abstract
Diabetic maculopathy is the commonest cause of blindness patients with diabetes type 2. The gold standard of treatment was nearly 40 years laser therapy, which was not always completely successful.
In recent years, this therapy starts succeffully to combine with intravitreal application of substances that act against endothelial vascular growth factor. However, the mainstay of treatment still remains prevention in the form of compensation risk factors especially hyperglycemia, hypertension and dyslipidemia.
